CME/CE

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

Tune in for a deep dive into the evolving landscape of immuno-oncology (IO) in early-stage triple-negative breast cancer (TNBC). Our experts focus on identifying eligible patients for neoadjuvant and adjuvant IO regimens, understanding current and emerging treatment options, and effectively utilizing shared decision-making (SDM) techniques to tailor treatment plans. The activity also covers the importance of recognizing and managing immune-related adverse events (irAEs) in the perioperative setting. Learn to optimize the use of IO in early-stage TNBC and improve your patients’ outcomes and quality of life.

Are you up to date on the plethora of benefits patients may receive from SGLT2 inhibitors? Learn from a multidisciplinary faculty panel as they use patient case vignettes to review emerging evidence and evolving treatment guidelines related to cardio-renal-metabolic comorbidities such as type 2 diabetes, heart failure, chronic kidney disease, and management of patients post-MI. Tune in for the insights you need to enhance your practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.